Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06258941
Other study ID # IRB-2023-1683
Secondary ID
Status Not yet recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date June 1, 2024
Est. completion date May 31, 2026

Study information

Verified date February 2024
Source Purdue University
Contact Shih-Chun (Alvin) Kao, PhD
Phone 765-496-2213
Email kao28@purdue.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this randomized controlled trial is to learn about the effect of a 12-week school-based intervention combining mindfulness with high-intensity interval training (MF-HIIT), MF-only intervention, and HIIT-only intervention in relative to sedentary activities on executive function (EF) in 10-12 years old children. The main question it aims to answer is whether a 12-week school-based MF-HIIT intervention has larger beneficial effect on EF performance than that following a 12-week school-based MF-only and HIIT-only in relative to the sedentary activities. Multiple cohorts of participants will be recruited to participate this one-semester study, including the pretest, intervention, and posttest phases. During the pretest phase, participants an their parents will complete the following 1. Kaufman Brief Intelligence Test (KBIT) to assess intelligence quotient 2. Fitnessgram test to assess aerobic capacity, muscle endurance, flexibility, and body mass index 3. Child and Adolescent Mindfulness Measure (CAMM) questionnaire to assess dispositional mindfulness 4. Computerized tasks to assess EF 5. Parent-reported demographic and health information Following the pretest phase, participants will receive the 12-week classroom-based intervention, with the classroom as the intervention unit. Following the intervention and during the posttest phase, participants will complete the fitness, measures, EF measures, and dispositional mindfulness measure again. Researcher will compare the EFn outcome measures following the MF-HIIT, MF-only, and HIIT-only interventions with the sedentary activity intervention to see if MF and HIIT has beneficial effects on children's EF. Further, researcher will compare the EF measures following the MF-HIIT compared with MF-only and HIIT-only interventions to see if combining MF with HIIT has greater beneficial effects on children's EF than MF and HIIT alone.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 352
Est. completion date May 31, 2026
Est. primary completion date May 31, 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 10 Years to 12 Years
Eligibility Inclusion Criteria: - Age between 10-12 years old - Intelligence Quotient = 85 - Capable of performing exercise based on pre-participation health screening - No formal diagnosis of cognitive disorders (e.g., attention deficit hyperactivity disorder) and neurological diseases (e.g., epilepsy) Exclusion Criteria: - Age outside of the range of 10-12 years old - Intelligence Quotient < 85 - No capable of performing exercise based on pre-participation health screening - Has formal diagnosis of cognitive disorders (e.g., attention deficit hyperactivity disorder) and neurological diseases (e.g., epilepsy)

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
MF-HIIT
Two 10-min MF-HIIT sessions every school day during the 12-week intervention period. One session in the morning and one session in the afternoon.
HIIT-only
Two 10-min HIIT-only sessions every school day during the 12-week intervention period. One session in the morning and one session in the afternoon.
MF-only
Two 10-min MF-only sessions every school day during the 12-week intervention period. One session in the morning and one session in the afternoon.
Sedentary activity
Two 10-min sedentary sessions every school day during the 12-week intervention period. One session in the morning and one session in the afternoon.

Locations

Country Name City State
United States Purdue University West Lafayette Indiana

Sponsors (1)

Lead Sponsor Collaborator
Purdue University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Inhibition speed Inhibition speed will be assessed by the response time (ms) during a child-friendly flanker task. At the baseline (1-2 weeks) before intervention starts and after (1-2 weeks) the intervention ends
Primary Inhibition accuracy Inhibition accuracy will be assessed by the response accuracy (percent) during a child-friendly flanker task. At the baseline (1-2 weeks) before intervention starts and after (1-2 weeks) the intervention ends
Primary Updating speed Updating speed will be assessed by the response time (ms) during a child-friendly n-back task. At the baseline (1-2 weeks) before intervention starts and after (1-2 weeks) the intervention ends
Primary Updating accuracy Updating accuracy will be assessed by the response accuracy (percent) during a child-friendly n-back task. At the baseline (1-2 weeks) before intervention starts and after (1-2 weeks) the intervention ends
Primary Shifting speed Shifting speed will be assessed by the response time (ms) during a child-friendly switching task. At the baseline (1-2 weeks) before intervention starts and after (1-2 weeks) the intervention ends
Primary Shifting accuracy Shifting accuracy will be assessed by the response accuracy (percent) during a child-friendly switching task. At the baseline (1-2 weeks) before intervention starts and after (1-2 weeks) the intervention ends
Secondary Aerobic capacity Aerobic capacity will be assessed by the Progressive Aerobic Cardiovascular Endurance Run (PACER) test At the baseline (1-2 weeks) before intervention starts and after (1-2 weeks) the intervention ends
Secondary Upper body muscle endurance Upper body muscle endurance will be assessed by the push-ups test At the baseline (1-2 weeks) before intervention starts and after (1-2 weeks) the intervention ends
Secondary Core body muscle endurance Core body muscle endurance will be assessed by the curl-ups test At the baseline (1-2 weeks) before intervention starts and after (1-2 weeks) the intervention ends
Secondary Flexibility Flexibility will be assessed by the back-saver sit and reach test At the baseline (1-2 weeks) before intervention starts and after (1-2 weeks) the intervention ends
Secondary Body composition body composition will be assessed by the body mass index computed as weight (kg) / (height [m] * height [m]) At the baseline (1-2 weeks) before intervention starts and after (1-2 weeks) the intervention ends
Secondary Dispositional mindfulness Dispositional mindfulness will be assessed by the Child and Adolescent Mindfulness Measure questionnaire (CAMM). The questionnaire has 10 items and requires the respondents to rating each item using a 5-point likert scale from 0 (Never True) to 4 (Always True). Higher summed scores indicate higher levels of mindfulness At the baseline (1-2 weeks) before intervention starts and after (1-2 weeks) the intervention ends
See also
  Status Clinical Trial Phase
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1